{"id":"abrupt-cessation-of-semaglutide","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia rebound"},{"rate":null,"effect":"Weight regain"},{"rate":null,"effect":"Loss of glycemic control"},{"rate":null,"effect":"Gastrointestinal symptom resolution"}]},"_chembl":{"chemblId":"CHEMBL4752331","moleculeType":"Unknown","molecularWeight":"4113.64"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Semaglutide is a GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon release in response to elevated blood glucose. Upon abrupt cessation, patients may experience rapid loss of these glycemic control benefits, potentially leading to hyperglycemia rebound, weight regain, and metabolic dysregulation. This study likely investigates the clinical consequences and optimal management strategies for discontinuing semaglutide therapy.","oneSentence":"Abrupt cessation of semaglutide involves the sudden discontinuation of a GLP-1 receptor agonist, which may result in rapid changes in glucose metabolism and metabolic rebound effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:58:36.372Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Obesity or weight management"}]},"trialDetails":[{"nctId":"NCT07294950","phase":"PHASE3","title":"Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination","status":"RECRUITING","sponsor":"Mount Sinai Hospital, Canada","startDate":"2026-02-01","conditions":"Obesity (Disorder), Weight Change, Blood Pressure Monitoring","enrollment":98}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Abrupt cessation of semaglutide","genericName":"Abrupt cessation of semaglutide","companyName":"Mount Sinai Hospital, Canada","companyId":"mount-sinai-hospital-canada","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abrupt cessation of semaglutide involves the sudden discontinuation of a GLP-1 receptor agonist, which may result in rapid changes in glucose metabolism and metabolic rebound effects. Used for Type 2 diabetes mellitus, Obesity or weight management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}